Company
Every investor coverage indicates participated in a round International Menopause Society raised.
Companies International Menopause Society acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Professor Susan Davis | President | Brandon BioCatalyst portfolio |
Stories naming International Menopause Society. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
QUE Oncology is moving its drug Q-122 into a Phase II proof-of-concept trial at Australian and US sites, targeting hot flushes in breast cancer patients on endocrine therapy, with Susan Davis leading the investigation.